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background:  Ticagrelor is commonly used as the P2Y12 inhibitor of choice in patients with acute coronary syndrome (ACS). Despite 
being superior to clopidogrel, clinicians may need to switch to a less potent P2Y12 inhibitor because of increased risk of bleeding, side 
effects, or cost.
objectives: The aim of this study was to identify the optimal dosing of clopidogrel when transitioning from ticagrelor to clopidogrel in ACS 
patients.
methods:  Patients with an indication to switch were randomized to either the bolus arm (clopidogrel 600mg bolus followed by 75mg daily, 
n=30) or the no-bolus arm (clopidogrel 75mg daily, n=30). Blood samples were collected at baseline and at 12, 24, 48, 54, 60 and 72 hours 
and platelet reactivity assessed using the VerifyNow P2Y12 assay. The primary outcome was platelet reactivity units (PRU) at 72 hours. 
Secondary outcomes included PRUs at each time point, proportion of patients with high on treatment platelet reactivity (HTPR, PRU>208), 
and major adverse cardiac events (MACE) defined as cardiovascular mortality, re-infarction, urgent revascularization and stroke were 
evaluated at 30-days.
Results:  PRUs increased after transition to clopidogrel in both groups and at 72 hours there was no difference between the bolus and no-
bolus regimens (165.8 +/- 71 vs 184.1 +/- 68, p=0.34); however, PRUs at 48 hours was lower in the bolus arm (114 ± 73.1 vs. 165.1 ± 70.5, 
respectively; p=0.01). Importantly, HTPR occurred in 17 patients in the no-bolus arm and 8 patients in the bolus arm (57% vs 27%, p=0.04). 
No differences in MACE, TIMI major bleeding or stent thrombosis were observed between the treatment strategies.
conclusion:  A bolus dose of clopidogrel was not associated with improved platelet inhibition at 72 hours; however at 48 hours platelet 
inhibition was superior and the incidence of HTPR was significantly reduced in patients receiving a bolus of clopidogrel with no increase in 
major bleeding. ACS patients transitioning from ticagrelor to clopidogrel should receive a bolus to reduce the risk of HTPR.
